NCT02528318 - Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

August 11, 2017

Conditions

Respiratory Distress Syndrome

Interventions

COMBINATION_PRODUCT

Lucinactant for inhalation

Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)

DEVICE

nCPAP alone

nCPAP therapy

Trial Locations (20)

10032

Columbia University College of Physicians and Surgeons, New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York

19713

Christiana Care Health System, Newark

28401

New Hanover Regional Medical Center, Wilmington

33136

University of Miami, Miami

40202

University of Louisville, Louisville

68105

University of Nebraska Medical Center, Omaha

92123

Sharp Mary Birch Hospital for Women and Newborns, San Diego

92354

Loma Linda University Medical Center, Loma Linda

97225

Providence St. Vincent Medical Center, Portland

8207257

Hospital Dr Sotero Del Rio, Santiago

8350488

Hospital San Juan de Dios, Santiago

02905

Women and Infants Hospital, Providence

T2N 2T9

Foothills Medical Centre, Calgary

T5H 3V9

Royal Alexandria Hospital, Edmonton

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

H4A 3J1

Montreal Children's Hospital, Montreal

60-535

Ginekologiczno-Polozniczy Szpital Klinicznym UM im. Karola Marcinkowskiego w Poznan i u Katedra Neonatologii, Poznan

85-168

S.U. nr2im. Dr. Jana Biziela Oddzial Kliniczny N. W. Z. Intensywna Terapia Noworodka wraz z Wgjazdowy m Zespolem N, Bydgoszcz

00-315

Szpital Kliniczny im. Ks, Anny Mazowieckiej Klinika Neonatologii, Warsaw

93-338

Instytut Centrum Zdrowja Matki Polki Klinika Neonatologii, Lodz